A dermatological preparation comprises an optimized, modified human embryonic fertility culture media with biguanides and/or functional equivalents and the use of said preparation for skin care, hair care, or body care, or dental procedures, or for regenerative medicine such as promoting wound or bone healing. The preparation is formulated to target the hypoxic microenvironment niches of the skin tissue in combination with optimal concentration of nutrients, ions and minerals; to stimulate existing stem cells to trigger the capacity of stem cells to divide and renew and differentiate into specialized cells; and to stimulate molecular and physiological processes, e.g., autophagy, to replenish the substrate pool through the recycling of organelles and the recycling of old damaged proteins and countering free-radical damage to promote anti-aging.

The present disclosure provides imaging agents that are useful for the detection and evaluation of heart conditions, such as myocardial infarction. Upon activation, the imaging agents of the present disclosure may be detected using an ultrasound imaging device.

The present invention relates to an oral pharmaceutical composition containing pemetrexed as a water-soluble anticancer drug and a method of manufacturing the same, and more particularly to an oral pharmaceutical composition, in which an ion-binding complex of pemetrexed and a bile acid derivative as an oral absorption enhancer is formed, mixed with a pharmaceutical additive, and then provided in the form of a capsule or a tablet through pressing or included in the internal water phase of a w/o/w (water-in-oil-in-water) multiple nanoemulsion, thus increasing the oral bioavailability of pemetrexed as the water-soluble anticancer drug, whereby pemetrexed, which is currently administered only in the form of an injection formulation, can be manufactured into a formulation capable of being orally administered, ultimately alleviating inconvenience and problems with use of injection formulations, improving patient compliance and contributing to a reduction in medical expenses.

The present invention relates to an oral pharmaceutical composition containing pemetrexed as a water-soluble anticancer drug and a method of manufacturing the same, and more particularly to an oral pharmaceutical composition, in which an ion-binding complex of pemetrexed and a bile acid derivative as an oral absorption enhancer is formed, mixed with a pharmaceutical additive, and then provided in the form of a capsule or a tablet through pressing or included in the internal water phase of a w/o/w (water-in-oil-in-water) multiple nanoemulsion, thus increasing the oral bioavailability of pemetrexed as the water-soluble anticancer drug, whereby pemetrexed, which is currently administered only in the form of an injection formulation, can be manufactured into a formulation capable of being orally administered, ultimately alleviating inconvenience and problems with use of injection formulations, improving patient compliance and contributing to a reduction in medical expenses.

A multicompartment system of nanocapsule-in-nanocapsule type based on hyaluronic acid derivative is designed for encapsulation of peptides and/or hydrophobic active compounds, either simultaneously or separately, where surfactants, emulsifiers and/or stabilizers are not required for the system stability. The system functions as a carrier which enables protection of sensitive hydrophilic substances against aggressive external environment, and the resulting degradation and deactivation, and makes it possible to concurrently administer active substances of varied hydrophilicity. A method is provided of producing a multicompartment nanocapsule-in-nanocapsule system in the form of water-in-oil-in-water double emulsion.

A multicompartment system of nanocapsule-in-nanocapsule type based on hyaluronic acid derivative is designed for encapsulation of peptides and/or hydrophobic active compounds, either simultaneously or separately, where surfactants, emulsifiers and/or stabilizers are not required for the system stability. The system functions as a carrier which enables protection of sensitive hydrophilic substances against aggressive external environment, and the resulting degradation and deactivation, and makes it possible to concurrently administer active substances of varied hydrophilicity. A method is provided of producing a multicompartment nanocapsule-in-nanocapsule system in the form of water-in-oil-in-water double emulsion.

The invention provides a compartmentalised gel matrix comprising one or more compartments, wherein each compartment comprises a volume of hydrophobic medium and one or more aqueous droplets therein. The invention further provides a pharmaceutical formulation comprising a compartmentalised gel matrix according to the invention, a synthetic cell comprising a compartmentalised gel matrix according to the invention and a synthetic tissue comprising a compartmentalised gel matrix according to the invention.

Methods for the formulation of biodegradable microparticles for delivery of protein drugs, such as botulinum toxin, have been developed. The methods include the steps of precipitating and washing proteins with organic solvent to remove water prior to dispersing in polymer-dissolved organic solvent to prevent exposure to water/solvent interfaces and maintain bioactivity of the protein drugs and fabrication of microparticles by either template or emulsion method. Biodegradable microparticles, formed of one or more biodegradable polymers having entrapped in the polymer one or more protein agents, such as botulinum toxin, are also provided. Precipitated botulinum toxin and botulinum toxin-loaded microparticles can also be formulated into thermogels or crosslinked hydrogels. The stability of the protein within these microparticles, as well as the controlled release of the entrapped agents, provides for sustained efficacy of the agents.

The present disclosure provides imaging agents that are useful for the detection and evaluation of heart conditions, such as myocardial infarction. Upon activation, the imaging agents of the present disclosure may be detected using an ultrasound imaging device.

Disclosed is a water-in-oil-in-water (W/O/W) double emulsion including a first water phase, an oil phase and a second water phase, wherein the W/O/W double emulsion is disposed in an isotonic solution, and related methods of making the W/O/W double emulsion. Also disclosed is a method of making an artificial antigen presenting cell including: providing a W/O/W double emulsion that is stored in an isotonic solution, wherein the W/O/W double emulsion includes a peptide associated with a Major Histocompatibility (pMHC) complex or a glycolipid antigen associated with a CD1d molecule, and a costimulatory molecule; and transferring the W/O/W double emulsion to an electrolyte solution, wherein the double emulsion undergoes a morphological transformation to become the artificial antigen presenting cell. Also disclosed is a method of drug delivery including administering to a subject a unilamellar vesicle containing the drug. Other methods relate to storing a protein including making a water-in-oil-in-water (W/O/W) double emulsion, wherein the W/O/W double emulsion includes the protein, and wherein the W/O/W double emulsion is configured to be stably stored.